VC  Windham Venture Partners

http://www.windhamvp.com/





     Office Locations:

1325 Avenue of the Americas
27th Floor
New York, NY 10019
Phone: 212-763-8525
Fax: 917-591-7274

Get all office locations for this firm with a National Database subscription or Silicon Valley Database subscription.
 

Stages:

  • Early
  • Expansion
  • Growth
  • Late


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Windham Venture Partners is a venture capital firm focused on health care, with particular emphasis on medical devices and diagnostics. The firm created the Windham Venture Partners Fund, which held its first closing in May, 2012. The fund has a target size of $75-$100 million and is actively seeking investment opportunities.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Adam Fine Co-Founder and CEO
    Joe Proto Co-Founder and Venture Partner
    Lorne Taichman Director of Science and Technology
    Roger Fine Co-Founder and General Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      01/24/2018


      Neuspera Medical


      CA


      $26,000,000


      Series B


      01/04/2018


      Personal Genome Diagnostics


      MD


      $75,000,000


      Series B


     

    Portfolio companies include:


      Cartiva
        web link


      Coravin
        web link


      CVRx
        web link


      Neuspera Medical
        web link


      Personal Genome Diagnostics
        web link


      VytronUS
        web link


      WellDoc
        web link


     

    Recent News: